ePrints

A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy

Lookup NU author(s): Emeritus Professor David Bates

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Background:Natalizumab is a highly effective treatment for patients with relapsing remitting multiple sclerosis (RRMS). Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), a rare yet serious disease of the brain. Published studies have quantified the PML risk by the presence of anti-JC virus antibodies, previous immunosuppressant use, and duration of natalizumab treatment.Objectives:The aim of this analysis was to evaluate the net benefits and risks for patients with RRMS receiving natalizumab treatment compared with fingolimod, interferon-beta, and no treatment across PML risk sub-groups.Research design and methods:Based on previously validated MS model structures, a Markov cohort model was developed to assess the impact of treatment on quality-adjusted life years (QALYs). Natalizumab-treated patients were classified by PML risk sub-groups and analysed separately for short-term (2 years) and long-term (20 years) time horizons.Main outcome measures:Main outcome measures included total QALYs by PML risk sub-group and the increase in PML risk associated with natalizumab treatment which offsets the quality of life benefit of comparator treatments.Results:Results showed higher QALYs with natalizumab versus all other comparators across PML risk sub-groups over both time horizons. For the QALYs of natalizumab to equal the QALYs of fingolimod, interferon-beta, and no treatment, the risk of PML would have to increase 4.6-84.2 times, 24.0-444.3 times, and 5.7-106.1 times, respectively (short term), and 1.4-123.4 times, 1.5-138.3 times, and 2.2-193.7 times, respectively (long term).Conclusion:This study shows that natalizumab generates the most net health benefits in terms of quality-adjusted life years compared with fingolimod, interferon-beta, or no treatment, even when the risk of natalizumab-associated PML is taken into consideration. This study is limited by the availability of published data around natalizumab-associated PML, as well as the constraints of the model used to conduct the analysis.

Publication metadata

Author(s): Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D

Publication type: Article

Publication status: Published

Journal: Current Medical Research and Opinion

Year: 2014

Volume: 30

Issue: 4

Pages: 629-635

Print publication date: 01/04/2014

ISSN (print): 0300-7995

ISSN (electronic): 1473-4877

Publisher: Informa Healthcare

URL: http://dx.doi.org/10.1185/03007995.2013.869492

DOI: 10.1185/03007995.2013.869492

Altmetrics

Share